Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects

Cancers

Volumn 3, Issue 1, 2011, Pages 1351-1371

  Florea, Ana Maria ^a   Büsselberg, Dietrich ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b QATAR FOUNDATION   (Qatar)

Author keywords

Apoptosis; Cancer; Cell death; Cisplatin; Combinatorial therapy; DNA damage and repair; Intracellular mechanisms; Multi drug resistance; ROS; ROS intracellular calcium; Toxicity

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CARBOPLATIN; CCAAT BINDING FACTOR; CCAAT BINDING FACTOR 2; CISPLATIN; GEMCITABINE; GLUTATHIONE TRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MARCKS PROTEIN; OXALIPLATIN; PICOPLATIN; PLATINUM COMPLEX; SATRAPLATIN; TRIPLATIN TETRANITRATE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; BIOMECHANICS; BONE MARROW SUPPRESSION; CALCIUM SIGNALING; CARCINOGENICITY; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL DIVISION; CELL FUNCTION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG EFFICACY; DRUG RESISTANCE; EPIGENETICS; GENE MUTATION; HEARING LOSS; HOMEOSTASIS; HUMAN; HYDRATION; INFECTION; LIPID PEROXIDATION; MITOCHONDRION; MOLECULAR DYNAMICS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; VOMITING;

EID: 79953700297     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3011351     Document Type: Review

References (77)

1. Frezza, M.; Hindo, S.; Chen, D.; Davenport, A.; Schmitt, S.; Tomco, D.; Dou, Q.P. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des. 2010, 16, 1813-1825.
2. Rosenberg, B. In Nucleic Acid-Metal Ion Interactions; Spiro, T.G., Ed.; John Wiley & Sons, Inc.: New York, NY, USA, 1980; Volume 1, pp. 1-29.
3. Desoize, B.; Madoulet, C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42, 317-325.
4. Che, C.M.; Siu, F.M. Metal complexes in medicine with a focus on enzyme inhibition. Curr. Opin. Chem. Biol. 2010, 14, 255-261.
5. Chen, D.; Milacic, V.; Frezza, M.; Dou, Q.P. Metal complexes, their cellular targets and potential for cancer therapy. Curr. Pharm. Des. 2009, 15, 777-791.
6. Zhang, J.; Wang, L.; Xing, Z.; Liu, D.; Sun, J.; Li, X.; Zhang, Y. Status of bi-and multi-nuclear platinum anticancer drug development. Anticancer Agents Med. Chem. 2010, 10, 272-282.
7. Lebwohl, D.; Canetta, R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer. 1998, 34, 1522-1534.
8. Olszewski, U.; Hamilton G. A better platinum-based anticancer drug yet to come? Anticancer Agents Med. Chem. 2010, 10, 293-301.
9. Shah, N.; Dizon, D.S. New-generation platinum agents for solid tumors. Future Oncol. 2009, 5, 33-42.
10. Günes, D.A.; Florea, A.M.; Splettstoesser, F.; Büsselberg, D. Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity. Neurotoxicology 2009, 30, 194-202.
11. Florea, A.-M.; Büsselberg, D. Metals and metal compounds: Occurrence, use, benefits and toxic cellular effects. Biometals 2006, 19, 419-427.
12. Tsang, R.Y.; Al-Fayea, T.; Au, H.J. Cisplatin overdose: Toxicities and management. Drug Saf. 2009, 32, 1109-1122.
13. Knoll, C; Smith, R.J.; Shores, C; Blatt, J. Hearing genes and cisplatin deafness: A pilot study. Laryngoscope 2006, 116, 72-74.
14. Rademaker-Lakhai, J.M.; Crul, M.; Zuur, L.; Baas, P.; Beijnen, J.H.; Simis, Y.J.; van Zandwijk, N.; Schellens, J.H. Relationship between Cisplatin administration and the development of ototoxicity. J. Clin. Oncol. 2006, 24, 918-924.
15. Drottar, M.; Liberman, M.C.; Ratan, R.R.; Roberson, D.W. The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope 2006, 116, 292-296.
16. Momekov, G.; Ferdinandov, D.; Bakalova, A.; Zaharieva, M.; Konstantinov, S.; Karaivanova, M. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands. Arch. Toxicol. 2006, 80, 555-560.
17. Liu, M.; Chien, C.C.; Burne-Taney, M.; Molls, R.R.; Racusen, L.C.; Colvin, R.B.; Rabb, H.A. Pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006, 17, 765-774.
18. Masubuchi, Y.; Kawasaki, M.; Horie, T. Down-regulation of hepatic cytochrome P450 enzymes associated with cisplatin-induced acute renal failure in male rats. Arch. Toxicol. 2006, 80, 347-353.
19. Trevisan, A.; Borella-Venturini, M.; Di Marco, L.; Fabrello, A.; Giraldo, M.; Zanetti, E.; Marzano, C.; Fregona, D. Erythrocyte aminolevulinic acid dehydratase inhibition by cisplatin. Toxicol. Lett. 2004, 152, 105-110.
20. Keller, G.A.; Ponte, M.L.; Di Girolamo, G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr. Drug Saf. 2010, 5, 105-111.
21. Pratibha, R.; Sameer, R.; Rataboli, P.V.; Bhiwgade, D.A.; Dhume, C.Y. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur. J. Pharmacol. 2006, 532, 290-293.
22. King, M.; McConkey, C.; Latief, T.N.; Hartley, A.; Fernando, I. Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects. Clin. Oncol. (R Coll. Radiol.) 2006, 18, 38-45.
23. Garcia, J.A.; Dreicer, R. Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nat. Clin. Pract. Urol. 2005, 2, 32-37.
24. Ralph, S.J.; Neuzil, J. Mitochondria as targets for cancer therapy. Mol. Nutr. Food Res. 2009, 53, 9-28.
25. Basu, S.; Ma, R.; Boyle, P.J.; Mikulla, B.; Bradley, M.; Smith, B.; Basu, M.; Banerjee, S. Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis-Platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside. Glycoconj. J. 2004, 20, 563-577.
26. Brozovic, A.; Ambriović-Ristov, A.; Osmak, M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 2010, 40, 347-359.
27. Desoize, B. Cancer and metals and metal compounds: Part I-Carcinogenesis. Crit. Rev. Oncol. Hematol. 2002, 42, 1-3.
28. Jordan, P.; Carmo-Fonseca, M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 2000, 57, 1229-1235.
29. Sedletska, Y.; Giraud-Panis, M.J.; Malinge, J.M. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 2005, 5, 251-265.
30. Wang, Z.H.; Miao, X.P.; Tan, W.; Zhang, X.R.; Xu, B.H.; Lin, D.X. Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai Zheng 2004, 23, 865-868.
31. Chaney, S.G.; Campbell, S.L.; Bassett, E.; Wu, Y. Recognition and processing of cisplatin-and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005, 53, 3-11.
32. Schar, P.; Fasi, M.; Jessberger, R. SMC1 coordinates DNA double-strand break repair pathways. Nucl. Acid. Res. 2004, 32, 3921-3929.
33. Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat 2005, 8, 131-146.
34. Benedetti, M.; Ducani, C.; Migoni, D.; Antonucci, D.; Vecchio, V.; Ciccarese, A.; Romano, A.; Verri, T.; Ciccarella, G.; Fanizzi, F. Experimental evidence that a DNA polymerase can incorporate N7-platinated guanines to give platinated DNA. Angew. Chem. Int. Ed. 2008, 47, 507-510.
35. Coluccia, M.; Natile, G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med. Chem. 2007, 7, 111-123.
36. Di Francesco, A.M.; Ruggiero, A.; Riccardi, R. Cellular and molecular aspects of drugs of the future: Oxaliplatin. Cell. Mol. Life Sci. 2002, 59, 1914-1927.
37. Shamimi-Noori, S.; Yeow, W.S.; Ziauddin, M.F.; Xin, H.; Tran, T.L.; Xie, J.; Loehfelm, A.; Patel, P.; Yang, J.; Schrump, D.S.; Fang, B.L.; Nguyen, D.M. Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther. 2008, 15, 356-370.
38. Wenger, T.; Mattern, J.; Penzel, R.; Gassler, N.; Haas, T.L.; Sprick, M.R.; Walczak, H.; Krammer, P.H.; Debatin, K.M.; Herr, I. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Difer. 2006, 13, 1740-1751.
39. Bellail, A.C.; Qi, L.; Mulligan, P.; Chhabra, V.; Hao, C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 2009, 4, 34-41.
40. Wu, X.X.; Ogawa, O.; Kakehi, Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam. Horm. 2004, 67, 365-383.
41. Hail, N., Jr.; Lotan, R. Cancer chemoprevention and mitochondria: Targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state. Mol. Nutr. Food Res. 2009, 53, 49-67.
42. Qian, W.; Nishikawa, M.; Haque, A.M.; Hirose, M.; Mashimo, M.; Sato, E.; Inoue, M. Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death. Am. J. Physiol. Cell Physiol. 2005, 289, C1466-C1475.
43. Muscella, A.; Calabriso, N.; Fanizzi, F.P.; De Pascali, S.A.; Urso, L.; Ciccarese, A.; Migoni, D.; Marsigliante, S. Pt[(O, O'-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity inMCF-7 breast cancer cells via the mitochondrial apoptotic pathway. Br. J. Pharmacol. 2008, 153, 34-49.
44. Wallace, K.B. Mitochondrial off targets of drug therapy. Trends Pharmacol. Sci. 2008, 29, 361-366.
45. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria as targets for chemotherapy. Apoptosis 2009, 14, 624-640.
46. Bossi, G.; Lapi, E.; Strano, S.; Rinaldo, C.; Blandino, G.; Sacchi, A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006, 25, 304-309.
47. Park, C.M.; Park, M.J.; Kwak, H.J.; Moon, S.I.; Yoo, D.H.; Lee, H.C.; Park, I.C.; Rhee, C.H.; Hong, S.I. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int. J. Oncol. 2006, 28, 119-125.
48. Karger, A.G.; Basel Iioka, Y., Mishima, K.; Azuma, N.; Tsuchida, A.; Takagi, Y.; Aoki, T.; Saito, I. Overexpression of protein kinase Cdelta enhances cisplatin-induced cytotoxicity correlated with p53 in gastric cancer cell line. Pathobiology 2005, 72, 152-159.
49. Wang, H.; Qian, H.; Yu, J.; Zhang, X.; Zhang, L.; Fu, M.; Liang, X.; Zhan, Q.; Lin, C. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol. Ther. 2006, 5, 380-385.
50. Pivonkova, H.; Brazdova, M.; Kasparkova, J.; Brabec, V.; Fojta, M. Recognition of cisplatindamaged DNA by p53 protein: critical role of the p53 C-terminal domain. Biochem. Biophys. Res. Commun. 2006, 339, 477-484.
51. Abbosh, P.H.; Montgomery, J.S.; Starkey, J.A.; Novotny, M.; Zuhowski, E.G.; Egorin, M.J.; Moseman, A.P.; Golas, A.; Brannon, K.M.; Balch, C.; Huang, T.H.; Nephew, K.P. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006, 66, 5582-5591.
52. Wang, D.; Lippard, S.J. Cisplatin-induced post-translational modification of histones H3 and H4. J. Biol. Chem. 2004, 279, 20622-20625.
53. Bhatt, K.; Zhou, L.; Mi, Q.S.; Huang, S.; She, J.X.; Dong, Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol. Med. 2010, 16, 409-416.
54. Xie, S.Y.; Li, Y.J.; Wang, P.Y.; Jiao, F.; Zhang, S.; Zhang, W.J. miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells. Oncol. Rep. 2010, 23, 1693-1700.
55. Splettstoesser, F.; Florea, A.M.; Büsselberg, D. IP(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis. Br. J. Pharmacol. 2007, 151, 1176-1186.
56. Tomaszewski, A.; Büsselberg, D. Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology 2007, 28, 49-58.
57. Wang, S.J.; Bourguignon, L.Y. Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 19-24.
58. Maffucci, T.; Piccolo, E.; Cumashi, A.; Iezzi, M.; Riley, A.M.; Saiardi, A.; Godage, H.Y.; Rossi, C.; Broggini, M.; Iacobelli, S.; Potter, B.V.; Innocenti, P.; Falasca, M. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res. 2005, 65, 8339-8349.
59. Rodríguez-Enríquez, S.; Marín-Hernández, A.; Gallardo-Pérez, J.C.; Carreño-Fuentes, L.; Moreno-Sánchez, R. Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 2009, 53, 29-48.
60. Raymond, E.; Faivre, S.; Chaney, S.; Woynarowski, J.; Cvitkovic, E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 2002, 1, 227-235.
61. Dieras, V.; Girre, V.; Guilhaume, M.N.; Laurence, V.; Mignot, L. Oxaliplatin and ovarian cancer. Bull. Cancer. 2006, 93 (Suppl. 1), S35-S39.
62. Ganjavi, H.; Gee, M.; Narendran, A.; Parkinson, N.; Krishnamoorthy, M.; Freedman, M.H.; Malkin, D. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin. Cancer Gene Ther. 2006, 13, 415-419.
63. Lacy, J.; Loomis, R.; Grill, S.; Srimatkandada, P.; Carbone, R.; Cheng, Y.C. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV(+) nasopharyngeal carcinoma xenografts in SCID mice. Int. J. Cance 2006, 119, 309-316.
64. Basma, H.; El-Refaey, H.; Sgagias, M.K.; Cowan, K.H.; Luo, X.; Cheng, P.W. BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J. Biomed. Sci. 2005, 12, 999-1011.
65. Chattopadhyay, S.; Machado-Pinilla, R.; Manguan-Garcia, C.; Belda-Iniesta, C.; Moratilla, C.; Cejas, P.; Fresno-Vara, J.A.; de Castro-Carpeno, J.; Casado, E.; Nistal, M.; Gonzalez-Che, C.M.; Siu, F.M. Metal complexes in medicine with a focus on enzyme inhibition. Curr. Opin. Chem. Biol. 2010, 14, 255-261.
66. Ohta, T.; Ohmichi, M.; Hayasaka, T.; Mabuchi, S.; Saitoh, M.; Kawagoe, J.; Takahashi, K.; Igarashi, H.; Du, B.; Doshida, M.; Mirei, I.G.; Motoyama, T.; Tasaka, K.; Kurachi, H. Inhibition of phosphatidylinostitol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147, 1761-1769.
67. Florea, A.-M.; Büsselberg, D. Anti-cancer drugs interfere with intracellular calcium signaling. Neurotoxicology 2009, 30, 803-810.
68. Florea, A.-M.; Büsselberg, D. Cisplatin as an anti-tumour drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, in press.
69. Torigoe, T.; Izumi, H.; Ishiguchi, H.; Yoshida, Y.; Tanabe, M.; Yoshida, T.; Igarashi, T.; Niina, I.; Wakasugi, T.; Imaizumi, T.; Momii, Y.; Kuwano, M.; Kohno, K. Cisplatin resistance and transcription factors. Curr. Med. Chem. Anticancer Agents 2005, 5, 15-27.
70. Kartalou, M.; Essigmann, J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478, 23-43.
71. Righetti, S.C.; Perego, P.; Carenini, N.; Corna, E.; Dal Bo, L.; Cedrola, S.; La Porta, C.A.; Zunino, F. Molecular alterations of cells resistant to platinum drugs: Role of PKCalpha. Biochim. Biophys. Acta 2006, 1763, 93-100.
72. Xie, X.K.; Yang, D.S.; Ye, Z.M.; Tao, H.M. Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest. 2006, 24, 1-8.
73. Hall, M.D.; Okabe, M.; Shen, D.W.; Liang, X.J.; Gottesman, M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535.
74. Qiu, Y.Y.; Mirkin, B.L.; Dwivedi, R.S. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect. Prev. 2005, 29, 456-463.
75. Pogribny, I.P.; Filkowski, J.N.; Tryndyak, V.P.; Golubov, A.; Shpyleva, S.I.; Kovalchuk, O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 2010, 127, 1785-1794.
76. Mohammad, R.M.; Banerjee, S.; Li, Y.; Aboukameel, A.; Kucuk, O.; Sarkar, F.H. Cisplatininduced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer. 2006, 106, 1260-1268.
77. Akiyama, S.; Chen, Z.S.; Kitazono, M.; Sumizawa, T.; Furukawa, T.; Aikou, T. Mechanisms for resistance to anticancer agents and the reversal of the resistance. Hum. Cell. 1999, 12, 95-102.